1078132-25-8

Basic information

• Product Name: 3-phenyl-1-(4-isopropylphenyl)pyrazol-5(4H)-one
• Synonyms: 3-phenyl-1-(4-isopropylphenyl)pyrazol-5(4H)-one
• CAS NO: 1078132-25-8
• Molecular Weight: 278.354
• Mol File: 1078132-25-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-phenyl-1-(4-isopropylphenyl)pyrazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-phenyl-1-(4-isopropylphenyl)pyrazol-5(4H)-one(1078132-25-8)
• EPA Substance Registry System: 3-phenyl-1-(4-isopropylphenyl)pyrazol-5(4H)-one(1078132-25-8)

Safety Data

• Hazardous Substances Data: 1078132-25-8(Hazardous Substances Data)

Upstream product

• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 118427-29-5 (4-isopropylphenyl)hydrazine hydrochloride 
• 63693-65-2 4-isopropylphenylhydrazine 

Downstream Products

• 1078132-18-9 C₂₅H₂₁ClN₂O₂ 
• 1257976-06-9 3-phenyl-1-(4-isopropylphenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one 

Relevant articles and documents

Synthesis of Spiropentadiene Pyrazolones by Rh(III)-Catalyzed Formal sp3 C-H Activation/Annulation

A Rh-catalyzed enol-directed formal sp3 C-H activation/annulation of α-arylidene pyrazolones with alkynes has been developed. This reaction provides a convenient route to synthesize spiropentadiene pyrazolones in good to excellent yields at room temperature, exhibiting good functional group tolerance, gram scalability, and high regioselectivity. Of note, the α-arylidene pyrazolone was introduced as a novel C3 synthon in C-H activation/annulation.

Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis

As a continuation of our previous work that turned toward the identification of antimycobacterial compounds with innovative structures, two series of pyrazole derivatives were synthesized by parallel solution-phase synthesis and were assayed as inhibitors of Mycobacterium tuberculosis (MTB), which is the causative agent of tuberculosis. One of these compounds showed high activity against MTB (MIC = 4 μg/mL). The newly synthesized pyrazoles were also computationally investigated to analyze their fit properties to the pharmacophoric model for antitubercular compounds previously built by us and to refine structure-activity relationship analysis.